Figure 3. Changes in health-related quality of life and FEV1 over 1 year.
Top. Scores on the St. George's Respiratory Questionnaire (SGRQ). Lower scores indicate improvements in quality of life. P = 0.02 for tiotropium plus placebo versus tiotropium plus salmeterol at 52 weeks; P = 0.01 for tiotropium plus placebo versus tiotropium plus fluticasone–salmeterol at 52 weeks. Bottom. Mean prebronchodilator FEV1. P = 0.87 for tiotropium plus placebo versus tiotropium plus salmeterol at 52 weeks; P = 0.049 for tiotropium plus placebo versus tiotropium plus fluticasone–salmeterol at 52 weeks.